Zai Lab Limited (ZLAB)

NASDAQ: ZLAB · IEX Real-Time Price · USD
20.84
+1.44 (7.42%)
At close: May 20, 2024, 4:00 PM
20.79
-0.05 (-0.24%)
After-hours: May 20, 2024, 7:08 PM EDT
7.42%
Market Cap 2.06B
Revenue (ttm) 291.07M
Net Income (ttm) -338.95M
Shares Out 98.72M
EPS (ttm) -3.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 825,620
Open 19.93
Previous Close 19.40
Day's Range 19.93 - 21.07
52-Week Range 13.48 - 37.92
Beta 1.11
Analysts Strong Buy
Price Target 64.22 (+208.16%)
Earnings Date May 8, 2024

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia grav... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 2,175
Stock Exchange NASDAQ
Ticker Symbol ZLAB
Full Company Profile

Financial Performance

In 2023, Zai Lab's revenue was $266.72 million, an increase of 24.03% compared to the previous year's $215.04 million. Losses were -$334.62 million, -24.51% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price forecast is $64.22, which is an increase of 208.16% from the latest price.

Price Target
$64.22
(208.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

SHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China's National Medical Products Adm...

23 hours ago - Business Wire

Zai Lab Announces Participation in May and June Investor Conferences

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

4 days ago - Business Wire

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration...

6 days ago - Business Wire

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug App...

8 days ago - Business Wire

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corpo...

12 days ago - Business Wire

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate update...

5 weeks ago - Business Wire

Zai Lab Statement on Executive Management Team's Agreement on Share Activities

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondso...

5 weeks ago - Business Wire

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipe...

6 weeks ago - Business Wire

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--  Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progressio...

Other symbols: BMY
7 weeks ago - Business Wire

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demo...

Other symbols: NVCR
7 weeks ago - Business Wire

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential o...

2 months ago - Business Wire

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the final overall survival (OS) data from the Phase 3 randomized, double-blind, placebo-co...

2 months ago - Business Wire

Zai Lab Announces Participation in March Investor Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

2 months ago - Business Wire

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate update...

2 months ago - Business Wire

Top 5 Health Care Stocks That Are Preparing To Pump In February

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BIOLCNSPGILDREVB
3 months ago - Benzinga

Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate...

4 months ago - Business Wire

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2...

4 months ago - Business Wire

Zai Lab Announces Participation in January Investor Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

5 months ago - Business Wire

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China's National Healthcare S...

5 months ago - Business Wire

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

SHANGHAI, China and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2023, along with recent pr...

6 months ago - GlobeNewsWire

Zai Lab Announces Participation in November Investor Conferences

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate...

7 months ago - GlobeNewsWire

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET

7 months ago - GlobeNewsWire

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Pr...

8 months ago - GlobeNewsWire

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical ...

Other symbols: GMAB
9 months ago - Market Watch

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors Candidate precision medicine has shown encouraging clin...

9 months ago - GlobeNewsWire